These findings inspired us to investigate the therapeutic effects of cholesterol lowering drugs from the statin class of the HMG-CoA reductase inhibitors, such as lovastatin, on the in vivo and in vitro growth of ErbB2-positive breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.